Vivimed Labs Limited (BOM:532660)
India · Delayed Price · Currency is INR 7.43
+0.25 (3.48%)
At close: Feb 13, 2026
Vivimed Labs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 1,041 | 1,163 | 1,491 | 1,871 | 2,373 | 8,615 |
Other Revenue | 48.74 | 43.71 | 99.76 | 9.68 | 12.7 | 98.23 |
Revenue | 1,090 | 1,206 | 1,590 | 1,881 | 2,386 | 8,713 |
Revenue Growth (YoY) | -23.23% | -24.15% | -15.43% | -21.16% | -72.62% | -18.35% |
Cost of Revenue | 518.14 | 616.19 | 722.71 | 2,746 | 1,557 | 3,793 |
Gross Profit | 571.84 | 590.21 | 867.76 | -864.86 | 828.14 | 4,919 |
Selling, General & Admin | 278.03 | 288.15 | 361.63 | 350.65 | 386.21 | 1,969 |
Other Operating Expenses | 271.01 | 388.32 | 724.79 | 643.72 | 509.83 | 2,464 |
Operating Expenses | 769.36 | 878.71 | 1,286 | 1,186 | 1,079 | 4,988 |
Operating Income | -197.52 | -288.5 | -418.07 | -2,051 | -250.73 | -68.52 |
Interest Expense | -32.42 | -17.35 | -12.13 | -350.04 | -385.42 | -505.17 |
Currency Exchange Gain (Loss) | -0.51 | -0.51 | -13.34 | -0.07 | - | -91.3 |
Other Non Operating Income (Expenses) | -12.11 | -12.12 | -14.69 | -8.99 | -12.18 | -33.58 |
EBT Excluding Unusual Items | -242.56 | -318.48 | -458.23 | -2,410 | -648.33 | -698.57 |
Gain (Loss) on Sale of Assets | - | - | - | -4.13 | - | - |
Asset Writedown | - | - | - | -892.8 | - | - |
Pretax Income | -242.56 | -318.48 | -458.23 | -3,307 | -648.33 | -698.57 |
Income Tax Expense | 1.13 | 1.13 | -3.77 | -21.17 | 28.17 | 20.29 |
Earnings From Continuing Operations | -243.69 | -319.61 | -454.46 | -3,285 | -676.5 | -718.86 |
Net Income | -243.69 | -319.61 | -454.46 | -3,285 | -676.5 | -718.86 |
Net Income to Common | -243.69 | -319.61 | -454.46 | -3,285 | -676.5 | -718.86 |
Shares Outstanding (Basic) | 83 | 83 | 83 | 83 | 83 | 83 |
Shares Outstanding (Diluted) | 83 | 83 | 83 | 83 | 83 | 83 |
Shares Change (YoY) | 0.15% | - | - | - | - | - |
EPS (Basic) | -2.94 | -3.85 | -5.48 | -39.62 | -8.16 | -8.67 |
EPS (Diluted) | -2.94 | -3.85 | -5.48 | -39.62 | -8.16 | -8.67 |
Free Cash Flow | -231.95 | -62.82 | -260.3 | 303.54 | 111.3 | 5,673 |
Free Cash Flow Per Share | -2.79 | -0.76 | -3.14 | 3.66 | 1.34 | 68.42 |
Gross Margin | 52.46% | 48.92% | 54.56% | -45.99% | 34.72% | 56.46% |
Operating Margin | -18.12% | -23.91% | -26.29% | -109.03% | -10.51% | -0.79% |
Profit Margin | -22.36% | -26.49% | -28.57% | -174.69% | -28.36% | -8.25% |
Free Cash Flow Margin | -21.28% | -5.21% | -16.37% | 16.14% | 4.67% | 65.11% |
EBITDA | 22.8 | -86.26 | -218.66 | -1,859 | -67.91 | 486.43 |
EBITDA Margin | 2.09% | -7.15% | -13.75% | -98.86% | -2.85% | 5.58% |
D&A For EBITDA | 220.32 | 202.24 | 199.41 | 191.27 | 182.82 | 554.95 |
EBIT | -197.52 | -288.5 | -418.07 | -2,051 | -250.73 | -68.52 |
EBIT Margin | -18.12% | -23.91% | -26.29% | -109.03% | -10.51% | -0.79% |
Revenue as Reported | 1,090 | 1,206 | 1,590 | 1,881 | 2,386 | 8,713 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.